Objective: The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients. Abnormal coagulation profiles were reported to be associated with poor outcomes. In this study, we assessed the prognostic values of antithrombin (AT) activity levels and the impact of fresh frozen plasma (FFP) treatment on outcome. Materials and Methods: Conventional coagulation parameters as well as AT activity levels and outcomes of 104 consecutive critically ill acute respiratory distress syndrome (ARDS) patients with laboratory-confirmed COVID-19 disease were retrospectively analyzed. Patients with AT activity below 75% were treated with FFP. Maximum AT activity levels achieved in those patients were recorded. Results: AT activity levels at admission were significantly lower in nonsurvivors than survivors (73% vs. 81%). The cutoff level for admission AT activity was 79% and 58% was the lowest AT for survival. The outcome in those patients who had AT activity levels above 75% after FFP treatment was better than that of the nonresponding group. As well as AT, admission values of D-dimer, C-reactive protein, and procalcitonin were coagulation and inflammatory parameters among the mortality risk factors. Conclusion: AT activity could be used as a prognostic marker for survival and organ failure in COVID-19-associated ARDS patients. AT supplementation therapy with FFP in patients with COVID-19-induced hypercoagulopathy may improve thrombosis prophylaxis and thus have an impact on survival.
Objective: The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients. Abnormal coagulation profiles were reported to be associated with poor outcomes. In this study, we assessed the prognostic values of antithrombin (AT) activity levels and the impact of fresh frozen plasma (FFP) treatment on outcome. Materials and Methods: Conventional coagulation parameters as well as AT activity levels and outcomes of 104 consecutive critically ill acute respiratory distress syndrome (ARDS) patients with laboratory-confirmed COVID-19 disease were retrospectively analyzed. Patients with AT activity below 75% were treated with FFP. Maximum AT activity levels achieved in those patients were recorded. Results:AT activity levels at admission were significantly lower in nonsurvivors than survivors (73% vs. 81%). The cutoff level for admission AT activity was 79% and 58% was the lowest AT for survival. The outcome in those patients who had AT activity levels above 75% after FFP treatment was better than that of the nonresponding group. As well as AT, admission values of D-dimer, C-reactive protein, and procalcitonin were coagulation and inflammatory parameters among the mortality risk factors. Conclusion:AT activity could be used as a prognostic marker for survival and organ failure in COVID-19-associated ARDSpatients. AT supplementation therapy with FFP in patients with COVID-19-induced hypercoagulopathy may improve thrombosis prophylaxis and thus have an impact on survival.
Authors: Marco Ranucci; Andrea Ballotta; Umberto Di Dedda; Ekaterina Bayshnikova; Marco Dei Poli; Marco Resta; Mara Falco; Giovanni Albano; Lorenzo Menicanti Journal: J Thromb Haemost Date: 2020-05-06 Impact factor: 5.824
Authors: Jordan Kountchev; Klaudija Bijuklic; Romuald Bellmann; Christian J Wiedermann; Michael Joannidis Journal: Crit Care Date: 2005-09-19 Impact factor: 9.097
Authors: Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch Journal: Lancet Date: 2020-04-21 Impact factor: 79.321
Authors: Paola de Candia; Francesco Prattichizzo; Silvia Garavelli; Rosalba La Grotta; Annunziata De Rosa; Agostina Pontarelli; Roberto Parrella; Antonio Ceriello; Giuseppe Matarese Journal: iScience Date: 2021-07-22
Authors: Hend M Esmaeel; Heba A Ahmed; Mahmoud I Elbadry; Asmaa R Khalaf; Nesreen A Mohammed; Hamza A Mahmoud; Elhaisam M Taha Journal: Sci Rep Date: 2022-08-01 Impact factor: 4.996
Authors: Lukas Wettstein; Patrick Immenschuh; Tatjana Weil; Carina Conzelmann; Yasser Almeida-Hernández; Markus Hoffmann; Amy Kempf; Inga Nehlmeier; Rishikesh Lotke; Moritz Petersen; Steffen Stenger; Frank Kirchhoff; Daniel Sauter; Stefan Pöhlmann; Elsa Sanchez-Garcia; Jan Münch Journal: J Med Virol Date: 2022-09-03 Impact factor: 20.693